Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells.

Robertson MW 3rd, Wang M, Siegal GP, Rosenfeld M, Ashford RS 2nd, Alvarez RD, Garver RI, Curiel DT.

Cancer Gene Ther. 1998 Sep-Oct;5(5):331-6.

PMID:
9824053
2.

Strategy for achieving selective killing of carcinomas.

Garver RI Jr, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT.

Gene Ther. 1994 Jan;1(1):46-50.

PMID:
7584059
3.

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.

J Gene Med. 2003 Apr;5(4):300-10.

PMID:
12692864
4.

Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.

Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT.

Clin Cancer Res. 1995 Dec;1(12):1571-80.

5.
7.

Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter.

Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S.

Cancer Res. 1995 Jul 15;55(14):3105-9.

8.
10.

Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene.

Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T.

Cancer Res. 1994 Oct 15;54(20):5258-61.

11.

Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.

Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV.

J Gastrointest Surg. 2009 Jun;13(6):1044-51. doi: 10.1007/s11605-009-0839-1. Epub 2009 Mar 10.

PMID:
19277794
12.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

13.

Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene.

Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F.

Cancer Res. 1998 Oct 15;58(20):4577-80.

14.

[Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].

Xing Y, Lu G, Xiao Y, Zeng F, Zhang Q, Xiong P, Feng W.

Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1484-7. Chinese.

PMID:
12509912
15.

Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.

Shimura H, Suzuki H, Miyazaki A, Furuya F, Ohta K, Haraguchi K, Endo T, Onaya T.

Cancer Res. 2001 May 1;61(9):3640-6.

16.

Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.

Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, Niitsu Y, Nukiwa T.

Cancer Res. 2004 Jul 1;64(13):4611-20.

17.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

19.

Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.

Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, Adachi Y, Takayama K, Dall P, Curiel DT.

J Gene Med. 2004 Nov;6(11):1281-9.

PMID:
15368588
20.

Supplemental Content

Support Center